Novel avermectins produced by mutational biosynthesis

  • J Antibiot (Tokyo). 1991 Mar;44(3):357-65. doi: 10.7164/antibiotics.44.357.
C J Dutton  1 ,  S P Gibson ,  A C Goudie ,  K S Holdom ,  M S Pacey ,  J C Ruddock ,  J D Bu'Lock ,  M K Richards
Affiliations
  • 1. Central Research Division, Pfizer Ltd., Kent, England.
PMID: 2026561 DOI: 10.7164/antibiotics.44.357
Abstract

Avermectins with a wide range of novel C-25 substituents have been prepared by feeding carboxylic acids or their biosynthetic precursors to a Streptomyces avermitilis mutant strain ATCC 53568. This organism lacks the ability to form isobutyric and S-2-methylbutyric acids from their 2-oxo acid precursors and thus is unable to produce natural avermectins unless supplied with these acids. The novel avermectins produced by mutational biosynthesis possess broad-spectrum antiparasitic activity.

Products